Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2023

24-03-2023

Effects of uridine and nucleotides on hemostasis parameters

Authors: Merve Arı, Engin Sağdilek, Evren Kılınç, Mehmet Cansev, Kasım Özlük

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2023

Login to get access

Abstract

Several purinergic receptors have been identified on platelets which are involved in hemostatic and thrombotic processes. The aim of the present study was to investigate the effects of uridine and its nucleotides on platelet aggregation and hemostasis in platelet-rich plasma (PRP) and whole blood. The effects of uridine, UMP, UDP, and UTP at different final concentrations (1 to 1000 µM) on platelet aggregation were studied using an aggregometer. In PRP samples, platelet aggregation was induced by ADP, collagen and epinephrine 3 min after addition of uridine, UMP, UDP, UTP and saline (as a control). All thromboelastogram experiments were performed at 1000 µM final concentrations of uridine and its nucleotides in whole blood. UDP and UTP were also tested in thromboelastogram with PRP. Our results showed that UDP, and especially UTP, inhibited ADP- and collagen-induced aggregation in a concentration-dependent manner. In whole blood thromboelastogram experiments, UDP stimulated clot formation while UTP suppressed clot formation. When thromboelastogram experiments were repeated with PRP, UTP’s inhibitory effect on platelets was confirmed, while UDP’s stimulated clot forming effect disappeared. Collectively, our data showed that UTP inhibited platelet aggregation in a concentration-dependent manner and suppressed clot formation. On the other hand, UDP exhibited distinct effects on whole blood or PRP in thromboelastogram. These data suggest that the difference on effects of UTP and UDP might have arisen from the different receptors that they stimulate and warrant further investigation with regard to their in vivo actions on platelet aggregation and hemostasis.
Appendix
Available only for authorised users
Literature
14.
go back to reference Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S (2008) Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor. Thromb Haemost 100:261–270 PMID: 18690346CrossRefPubMed Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S (2008) Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor. Thromb Haemost 100:261–270 PMID: 18690346CrossRefPubMed
21.
go back to reference Goetz U, Da Prada M, Pletscher A (1971) Adenine-, guanine- and uridine-5’-phosphonucleotides in blood platelets and storage organelles of various species. J Pharmacol Exp Ther 178:210–215 PMID: 5087398PubMed Goetz U, Da Prada M, Pletscher A (1971) Adenine-, guanine- and uridine-5’-phosphonucleotides in blood platelets and storage organelles of various species. J Pharmacol Exp Ther 178:210–215 PMID: 5087398PubMed
Metadata
Title
Effects of uridine and nucleotides on hemostasis parameters
Authors
Merve Arı
Engin Sağdilek
Evren Kılınç
Mehmet Cansev
Kasım Özlük
Publication date
24-03-2023
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2023
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-023-02793-y

Other articles of this Issue 4/2023

Journal of Thrombosis and Thrombolysis 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.